Protagenic Therapeutics receives $3.1M from warrant exchanges and exercises

Protagenic Therapeutics, Inc.new

Warrant exchanges and exercises over the last four trading days generated $3.1M in cash.
Proceeds will fund working capital and advance peptide-based drug candidates for CNS disorders.
Company previously announced business combination with Phytanix Bio Inc. on May 19, 2025.
Combined entity has six drug programs spanning stress, epilepsy, obesity, and other indications.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.